Cytokinetics (NASDAQ:CYTK) Earns Media Impact Score of 0.22

Media coverage about Cytokinetics (NASDAQ:CYTK) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Cytokinetics earned a news impact score of 0.22 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.3447313164432 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:

How to Become a New Pot Stock Millionaire

Shares of NASDAQ:CYTK traded down $0.20 during trading on Thursday, hitting $7.10. The stock had a trading volume of 272,342 shares, compared to its average volume of 369,724. Cytokinetics has a 12-month low of $6.75 and a 12-month high of $17.20. The stock has a market cap of $423.96, a price-to-earnings ratio of -2.79 and a beta of 1.16. The company has a quick ratio of 8.46, a current ratio of 8.46 and a debt-to-equity ratio of 0.29.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.04). The firm had revenue of ($0.02) million during the quarter, compared to analysts’ expectations of $4.83 million. Cytokinetics had a negative return on equity of 96.95% and a negative net margin of 172.27%. equities analysts anticipate that Cytokinetics will post -1.81 EPS for the current fiscal year.

A number of analysts have recently commented on CYTK shares. HC Wainwright set a $20.00 price target on shares of Cytokinetics and gave the company a “buy” rating in a research report on Friday, January 19th. Cowen restated a “buy” rating and issued a $11.00 price target on shares of Cytokinetics in a research note on Tuesday, February 20th. Morgan Stanley increased their target price on Cytokinetics from $17.00 to $18.00 and gave the company an “overweight” rating in a research report on Wednesday, February 21st. Cantor Fitzgerald set a $10.00 target price on Cytokinetics and gave the company a “hold” rating in a research report on Monday, February 12th. Finally, BidaskClub upgraded Cytokinetics from a “strong sell” rating to a “sell” rating in a report on Tuesday, March 6th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $15.67.

In other news, CEO Robert I. Blum sold 4,000 shares of Cytokinetics stock in a transaction that occurred on Thursday, April 5th. The stock was sold at an average price of $7.52, for a total value of $30,080.00. Following the sale, the chief executive officer now directly owns 182,701 shares of the company’s stock, valued at $1,373,911.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 5.10% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Cytokinetics (NASDAQ:CYTK) Earns Media Impact Score of 0.22” was first posted by Week Herald and is the property of of Week Herald. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://weekherald.com/2018/04/19/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-cytokinetics-cytk-share-price.html.

Cytokinetics Company Profile

Cytokinetics, Inc operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS).

Insider Buying and Selling by Quarter for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply